Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5268648
Max Phase: Preclinical
Molecular Formula: C37H54N4O10S
Molecular Weight: 746.92
Associated Items:
ID: ALA5268648
Max Phase: Preclinical
Molecular Formula: C37H54N4O10S
Molecular Weight: 746.92
Associated Items:
Canonical SMILES: CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)cc1
Standard InChI: InChI=1S/C37H54N4O10S/c1-23(2)20-41(52(46,47)27-15-13-26(14-16-27)38-33(43)32(24(3)4)40-36(45)51-37(5,6)7)21-30(42)29(19-25-11-9-8-10-12-25)39-35(44)50-31-22-49-34-28(31)17-18-48-34/h8-16,23-24,28-32,34,42H,17-22H2,1-7H3,(H,38,43)(H,39,44)(H,40,45)/t28-,29-,30+,31-,32-,34+/m0/s1
Standard InChI Key: VMFIISLXRCBSPO-VIEXPPAXSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 746.92 | Molecular Weight (Monoisotopic): 746.3561 | AlogP: 4.28 | #Rotatable Bonds: 15 |
Polar Surface Area: 181.83 | Molecular Species: NEUTRAL | HBA: 10 | HBD: 4 |
#RO5 Violations: 1 | HBA (Lipinski): 14 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 12.35 | CX Basic pKa: | CX LogP: 4.91 | CX LogD: 4.91 |
Aromatic Rings: 2 | Heavy Atoms: 52 | QED Weighted: 0.21 | Np Likeness Score: -0.29 |
1. Ghosh AK, Shahabi D, Kipfmiller M, Ghosh AK, Johnson M, Wang YF, Agniswamy J, Amano M, Weber IT, Mitsuya H.. (2023) Evaluation of darunavir-derived HIV-1 protease inhibitors incorporating P2' amide-derivatives: Synthesis, biological evaluation and structural studies., 83 [PMID:36738797] [10.1016/j.bmcl.2023.129168] |
Source(1):